Suggestions
John Swartley
Chief Innovation Officer, University of Pennsylvania
John Swartley is the Chief Innovation Officer at the University of Pennsylvania, a position he has held since January 2024.14 With a career spanning over two decades in innovation and technology transfer, Swartley has been instrumental in shaping Penn's reputation as a leader in commercializing academic research.
Career at Penn
Swartley joined Penn in 2007 as the Senior Director and Head of New Ventures for the Center for Technology Transfer.4 He then served as the Associate Vice Provost for Research and Managing Director of the Penn Center for Innovation (PCI) for nearly a decade before his promotion to Chief Innovation Officer.13 In this role, he is responsible for implementing and leading a university-wide innovation agenda, working closely with Penn's leadership, deans, and external partners.3
Achievements
Under Swartley's leadership, Penn has achieved significant success in technology commercialization:
- In 2021, PCI supported 142 initiatives that earned a United States-issued patent.1
- Penn ranked first in licensing income across over 150 participating institutions in 2021.1
- In 2022, Penn's licensing earnings reached $1 billion.1
Background and Education
Swartley holds a B.S. in Biology from Bates College, an MBA from the Goizueta School of Business at Emory University, and a PhD in Microbial & Molecular Genetics from Emory University.34
Impact on Innovation
Throughout his career, Swartley has facilitated thousands of commercialization agreements, generating nearly $5 billion in licensing income and research funding.2 He has also overseen the creation of hundreds of university spinouts, contributing billions in capital.2 His approach focuses on transforming academic research into real-world companies, particularly in fields such as AI, fintech, medtech, cell and gene therapy, cancer research, and vaccines.2
Swartley's vision and leadership have been crucial in elevating Penn's status as a global leader in technology transfer, particularly in the commercialization of next-generation technologies like mRNA vaccines.2



